MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication

in boston •  7 years ago 

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Immune System Diseases and Conditions - HIV/AIDS. According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, “Men who have sex with men (MSM) account for nearly 70% of new HIV diagnoses, with young black MSM at the highest risk for infection in the United States. Pre-exposure prophylaxis (PrEP) can decrease HIV acquisition in at-risk individuals by over 90%.”

Funders for this research include ViiV Healthcare, Harvard University Center for AIDS Research.

Our news journalists obtained a quote from the research from Fenway Institute, “However, therapeutic efficacy requires a daily pill, posing adherence challenges. Experimental modalities, including injectable PrEP given once every 2 months, may improve adherence among those most in need. To assess interest in and preference for injectable PrEP, an online survey was mounted on two popular MSM sexual networking apps. Differences by age, race, and other characteristics were examined using multinomial logistic regressions. Of 4638 respondents, 73% expressed interest in injectable PrEP and 47% indicated they would prefer an injection (compared to 17% who prefer a daily pill and 36% who were unsure). Within this sample, interest in and preference for injectable PrEP was highest among MSM at highest risk for HIV infection (i.e., younger age groups, racial/ethnic minorities, those with risker sexual behavior).”

According to the news editors, the research concluded: “As a result, if proven effective in clinical trials, injectable PrEP has the potential to reduce social disparities in HIV transmission among MSM.”

For more information on this research see: MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication. AIDS and Behavior , 2018;22(4):1158-1164. AIDS and Behavior can be contacted at: Springer, Plenum Publishers, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; AIDS and Behavior - http://www.springerlink.com/content/1090-7165/)

The news correspondents report that additional information may be obtained from K.B. Biello, Fenway Inst, Fenway Hlth, Boston, MA 02215, United States. Additional authors for this research include M.J. Mimiaga, C.M. Santostefano, D.S. Novak and K.H. Mayer.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10461-017-1972-6. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

CITATION: (2018-05-05), Reports on HIV/AIDS from Fenway Institute Provide New Insights (MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication), Obesity, Fitness & Wellness Week, 3126, ISSN: 1532-4664, BUTTER® ID: 015584340

From the newsletter Obesity, Fitness & Wellness Week.
https://www.newsrx.com/Butter/#!Search:a=15584340


This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.

We have been in business for more than 20 years and our full contact information is available on our main corporate website.

We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.

NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.

View Newsletter Titles

About NewsRx® and Contact Information

Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!
Sort Order:  

Congratulations @newsrx! You have completed some achievement on Steemit and have been rewarded with new badge(s) :

You published 4 posts in one day

Click on any badge to view your own Board of Honor on SteemitBoard.
For more information about SteemitBoard, click here

If you no longer want to receive notifications, reply to this comment with the word STOP

Upvote this notification to help all Steemit users. Learn why here!